REGENXBIO’s NAV® Technology has ushered in a new era of gene therapy innovation. We are leveraging our proprietary NAV Technology and collaborating with world-class clinical advisors to advance the development of life-changing gene therapy treatments for lysosomal storage disorders and ocular diseases. Beyond these core areas of focus, we are licensing NAV Technology to enable global strategic partners to advance gene therapy programs for other serious diseases with unmet needs, such as hemophilia, Pompe disease and spinal muscular atrophy.

NAV® Technology Licensees